ArticleERJ open research2021
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.
Open access · goldAbstract read
In one paragraph
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review.Frontiers in pediatrics · 2022Pooled it
- Cystic fibrosis care today-a narrative review based on views of experts, patients and the public.Wiener klinische Wochenschrift · 2026Review
- Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross-Sectional Study in Israel.Pediatric pulmonology · 2025Article
- Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.Journal of clinical medicine · 2025Article
- Success of the German Cystic Fibrosis Registry.Pharmacoepidemiology and drug safety · 2025Article
- Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients.Cureus · 2024Article
- Long-Term Assessment of Antibody Response to COVID-19 Vaccination in People with Cystic Fibrosis and Solid Organ Transplantation.Vaccines · 2024Article
- Occurrence of COVID-19 in cystic fibrosis patients: a review.Frontiers in microbiology · 2024Review
- The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review.Respiratory research · 2023Review
- Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis.Healthcare (Basel, Switzerland) · 2023Article
- Is There a Difference in Immune Response to SARS-CoV-2 Vaccination between Liver and Lung Transplant Patients with Cystic Fibrosis?Vaccines · 2023Article
- Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages.International journal of molecular sciences · 2023Review
- SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.Nature communications · 2023Article
- Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation.International journal of molecular sciences · 2023Article
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
- Incidence and Severity of SARS-CoV-2 Infections in People With Primary Ciliary Dyskinesia.International journal of public health · 2023Article
- The clinical features and impact of SARS-CoV-2/COVID-19 infection in children with Cystic Fibrosis (CF): A Qatari experience.Qatar medical journal · 2023Article
- Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes.Biomedicines · 2022Article
- Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.Archivos de bronconeumologia · 2022Review
- The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 33 countries.
Andreas JungPaediatric Pulmonology, University Children's Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-3505-6691
Annalisa OrentiDept of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G.A. Maccacaro, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-0932-2757
Fiona DunlevyEuropean Cystic Fibrosis Society, Karup, Denmark.
Elina AleksejevaDept of Pneumology, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia.
Egil BakkeheimDept of Paediatrics, Norwegian Cystic Fibrosis Registry, Oslo University Hospital, Oslo, Norway.
Vladimir BobrovnichyBelarusian Republic Children's Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children's Clinical Hospital, Minsk, Belarus.
Siobhán B CarrDept of Respiratory Paediatrics, Royal Brompton Hospital, London, UK.ORCID https://orcid.org/0000-0003-0580-2478
Carla ColomboDept of Pathophysiology and Transplantation, Cystic Fibrosis Reference Center of Lombardia Region, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Harriet CorvolPediatric Pulmonology Dept and Cystic Fibrosis Center, Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Paris, France.ORCID https://orcid.org/0000-0002-7026-7523
Rebecca CosgriffCystic Fibrosis Trust, London, UK.
Géraldine DaneauSciensano, Epidemiology and Public Health, Health Services Research, Brussels, Belgium.ORCID https://orcid.org/0000-0002-2570-0893
Deniz DogruCystic Fibrosis Registry of Turkey, Ankara, Turkey.ORCID https://orcid.org/0000-0001-9931-9473
Pavel DrevinekDept of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
Andrea Dugac VukicUniversity Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia.
Isabelle FajacUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France.
Alice FoxEuropean Cystic Fibrosis Society, Karup, Denmark.
Stojka FustikCentre for Cystic Fibrosis, University Children's Hospital, Skopje, North Macedonia.
Vincent GulmansDutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands.
Satenik HarutyunyanYerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.
Elpis HatziagorouCystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Irena KasmiDept of Paediatrics, "Mother Thereza" Hospital Center, Tirana, Albania.
Hana KayserováCystic Fibrosis Centre, University Hospital of Bratislava, Bratislava, Slovakia.
Elena KondratyevaClinical Research Dept of Cystic Fibrosis "Research Centre for Medical Genetics", Moscow, Russian Federation.
Uroš KrivecDept of Paediatric Pulmonology, University Children's Hospital, Ljubljana University Medical Centre, Ljubljana, Slovenia.ORCID https://orcid.org/0000-0001-9031-5708
Halyna MakukhInstitute of Hereditary Pathology, Ukrainian National Academy of Medical Sciences, Lviv, Ukraine.
Kestutis MalakauskasAdult Cystic Fibrosis Center, Dept of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Edward F McKoneSt Vincent's University Hospital & University College Dublin School of Medicine, Dublin, Ireland.
Meir Mei-ZahavPulmonary Institute, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
Isabelle de MonestrolStockholm CF Centre, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Hanne Vebert OlesenDept of Pediatrics and Adolescent Medicine, Cystic Fibrosis Center, Aarhus University Hospital, Aarhus, Denmark.
Rita PadoanDept of Paediatrics, Cystic Fibrosis Regional Support Centre, University of Brescia, Brescia.
Tsitsino ParulavaI. Tsitsishvili Children's Clinic, CF Centre, Tblisi, Georgia.ORCID https://orcid.org/0000-0003-2467-7940
Maria Dolores Pastor-ViveroPediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain.ORCID https://orcid.org/0000-0001-8917-4709
Luísa PereiraCentre for Cystic Fibrosis, Hospital de Santa Maria, Lisbon, Portugal.
Guergana PetrovaPediatric Clinic, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria.
Andreas PflegerDept of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria.
Liviu PopVictor Babes University of Medicine and Pharmacy Timisoara, National Cystic Fibrosis Centre, Timisoara, Romania.
Jacqui G van RensEuropean Cystic Fibrosis Society, Karup, Denmark.
Milan RodicNational Centre for Cystic Fibrosis, Mother and Child Health Institute of Serbia "Dr Vukan Čupić", Belgrade, Serbia.
Marc SchlesserDept of Pulmonology, Hôpital Robert Schuman, Luxembourg, Luxembourg.
Valérie StormsCystic Fibrosis Europe, Brussels, Belgium.ORCID https://orcid.org/0000-0001-9344-0248
Oxana TurcuDept of Pediatrics, Ambulatory Cystic Fibrosis and Other Rare Diseases Center, Institute for Maternal and Child Healthcare, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Republic of Moldova.
Lukasz Woz NiackiDziekanow Paediatric Hospital, Cystic Fibrosis Centre, Institute of Mother and Child, Warsaw, Poland.
Panayiotis YiallourosMedical School, University of Cyprus, Nicosia, Cyprus.
Anna ZolinDept of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G.A. Maccacaro, University of Milan, Milan, Italy.
Damian G DowneyWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Lutz NaehrlichDept of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G.A. Maccacaro, University of Milan, Milan, Italy.
University of Milan · ITHealth First · US9th City Clinical Hospital · BYAarhus University Hospital · DKAlexandrovska Hospital · BGAristotle University of Thessaloniki · GRBrescia University · USCharles University · CZChildren's Clinical University Hospital · LVCystic Fibrosis Trust · GBDélégation Paris 5 · FRHospital de Santa Maria · PTInserm · FRInstitute of Public Health of Serbia · RSKarolinska University Hospital · SELithuanian University of Health Sciences · LTLjubljana University Medical Centre · SIMedical University of Graz · ATMother Teresa Hospital · ALNational Academy of Sciences of Ukraine · UA
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.
methodsIn this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.
resultsUp to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7-35.5)
conclusionSARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.